MétaCan
Menu
Back to cohort

Abstract GS1-08: Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: results from an international cohort study

2025· article· en· W4411288963 on OpenAlexaboutno aff
Matteo Lambertini, Amir Sonnenblick, Elisa Agostinetto, Raphaëlle Bas, Maria Alice Franzoi, R. Bernstein Molho, Sabine Linn, Ava Kwong, Katarzyna Pogoda, Judith Balmañà, Ann Smeets, Jyoti Bajpai, Halle C. F. Moore, Ann H. Partridge, Kelly‐Anne Phillips, Angela Toss, Christine Rousset‐Jablonski, Fedro A. Peccatori, Tiphaine Renaud, Alberta Ferrari, Shani Paluch–Shimon, Pablo Mandó, Jeong Eon Lee, Robert Fruscio, Stephanie M. Wong, Claudio Vernieri, Kathryn J. Ruddy, Maria Vittoria Dieci, Alexios Matikas, Mariya Rozenblit, Deniz Can Güven, Minna Lee, Cynthia Villarreal‐Garza, Shelley Hwang, Laura De Marchis, Fabio Puglisi, Zoe Kemp, Pedro A. Meireles, Anastasia Parokonnaya, Gustavo Werutsky, Maiko Okano, Hatem A. Azim, Kleida Mati, Shoshana Rosenberg, Richard D. Gelber, Luca Boni, Eva Blondeaux

Bibliographic record

VenueClinical Cancer Research · 2025
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicBRCA gene mutations in cancer
Canadian institutionsnot available
Fundersnot available
KeywordsMedicineOncologyBreast cancerCohortCancerInternal medicineCohort study

Abstract

fetched live from OpenAlex

Abstract Background: In carriers of germline pathogenic/likely pathogenic variants (PVs) in BRCA1 and/or BRCA2 genes, cancer risk management strategies are widely recommended. While risk-reducing salpingo-oophorectomy (RRSO) has shown to improve overall survival (OS), bilateral risk-reducing mastectomy (RRM) reduces the risk of developing breast cancer (BC) but has no proven OS benefit. Very limited evidence exists on RRSO and/or RRM specifically in BRCA carriers with prior BC diagnosis at a young age. Here we investigated the association between RRM and/or RRSO with survival outcomes in the largest global cohort of young BRCA carriers with BC. Methods: The BRCA BCY Collaboration (NCT03673306) is an international, multicenter, hospital-based, retrospective cohort study including women harboring germline BRCA1 and/or BRCA2 PVs and diagnosed between January 2000 and December 2020 with stage I-III invasive BC at the age of 40 years or younger. Patients with no information on uptake or timing of RRM and/or RRSO, or their uptake before BC diagnosis and BRCA healthy carriers were excluded. Primary endpoint was OS. Disease-free survival (DFS) and BC-free interval (BCFI) were secondary endpoints. Survival endpoints were computed from BC diagnosis. To account for potential lead time bias, in the primary analysis Cox models were used to explore the association between RRM and RRSO both included as time-dependent covariates and survival outcomes. Stratification factors were year at BC diagnosis, region/country and nodal status; OS models were also adjusted by development of distant recurrences/second primary malignancies as time-dependent covariates. In addition, sensitivity analyses were performed including a 3-year landmark analysis and a subgroup analysis including only patients tested for BRCA before or within 6 months from BC diagnosis. Results: From 109 centers in 5 continents, 5290 patients were included. Median age at BC diagnosis was 35 years (IQR 31-38). A total of 3361 (63.5%) patients were BRCA1 carriers, 2708 (51.2%) had node-negative and 2421 (45.8%) hormone receptor-positive (HR+) BC. A total of 2910 (55.0%) patients underwent RRM and 2782 (52.6%) RRSO. Median time from BC diagnosis to RRM was 0.8 years (IQR 0.5-2.7) and to RRSO was 3.0 years (IQR 1.3-6.8); median follow-up was 5.1 years (IQR 2.7-8.3) after RRM and 4.9 years (IQR 2.3-8.1) after RRSO. At a median follow-up of 8.2 years (IQR, 4.7-12.8), 686 (13.0%) OS, 1923 (36.3%) DFS and 1751 (33.1%) BCFI events were observed. RRM was associated with a significantly reduced risk of OS events (adjusted HR [aHR] 0.65, 95% CI 0.53-0.78). This association was observed irrespective of specific BRCA gene, age at BC diagnosis, tumor subtype, tumor size and nodal status. RRM was also associated with a significantly reduced risk of DFS (aHR 0.58, 95% CI 0.52-0.65) and BCFI (aHR 0.55, 95% CI 0.48-0.62) events. RRSO was associated with a significantly reduced risk of OS events (aHR 0.58, 95% CI 0.48-0.71). This association was observed irrespective of age at BC diagnosis, tumor size and nodal status. A significant interaction was observed according to specific BRCA gene (BRCA1 carriers: aHR 0.44, 95% CI 0.34-0.57; BRCA2 carriers: aHR 0.85, 95% CI 0.64-1.15) and tumor subtype (triple-negative BC: aHR 0.44, 95% CI 0.33-0.58; HR+ BC: aHR 0.80, 95% CI 0.60-1.05). RRSO was also associated with a significantly reduced risk of DFS (aHR 0.68, 95% CI 0.61-0.77) and BCFI (aHR 0.65, 95% CI 0.57-0.74) events. Sensitivity analyses provided consistent results. Conclusions: In this unique international cohort of BRCA carriers with prior BC diagnosis at a young age, RRM and RRSO were both associated with a significant improvement in OS, DFS and BCFI. These findings are critical for improving the counseling of young BRCA carriers with BC on cancer risk management strategies. Citation Format: Matteo Lambertini, Amir Sonnenblick, Elisa Agostinetto, Raphaëlle Bas, Hee Jeong Kim, Maria Alice Franzoi, Rinat Bernstein Molho, Sabine Linn, Ava Kwong, Katarzyna Pogoda, Judith Balmana, Ann Smeets, Jyoti Bajpai, Halle C.F. Moore, Ann H. Partridge, Kelly-Anne Phillips, Angela Toss, Christine Rousset-Jablonski, Fedro A. Peccatori, Tiphaine Renaud, Alberta Ferrari, Shani Paluch-Shimon, Pablo Mando, Jeong Eon Lee, Robert Fruscio, Wanda Cui, Stephanie M. Wong, Claudio Vernieri, Kathryn J. Ruddy, Maria Vittoria Dieci, Alexios Matikas, Mariya Rozenblit, Deniz Can Guven, Minna Lee, Cynthia Villarreal-Garza, Shelley E. Hwang, Laura De Marchis, Fabio Puglisi, Zoe Kemp, Pedro A. Meireles, Anastasia Parokonnaya, Gustavo Werutsky, Maiko Okano, Hatem A. Azim, Kleida Mati, Shoshana Rosenberg, Richard Gelber, Luca Boni, Eva Blondeaux. Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: results from an international cohort study [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr GS1-08.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.004
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.012
Threshold uncertainty score0.024

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.004
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0010.002
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0010.001
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.056
GPT teacher head0.460
Teacher spread0.404 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueClinical Cancer ResearchSame topicBRCA gene mutations in cancerFrench-language works237,207